Coronavirus Drug Discovery
Volume 3: Druggable Targets and In Silico Update
- 1st Edition - July 12, 2022
- Latest edition
- Editor: Chukwuebuka Egbuna
- Language: English
Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of th… Read more
Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health.
In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful.
- Discusses the pathogenic mechanisms of SARS-CoV-2 and druggable targets
- Reviews the various signaling pathways associated with SAR-CoV-2 as possible druggable targets
- Presents computational approaches and in silico studies against SARS-CoV-2
Researchers in organic and medicinal chemistry including drug developers and medicinal chemists, virologists, toxicologists, analytical chemists. Researchers in pharmaceutical and biotech industries
PART 1: DRUGGABLE TARGETS AND SIGNALING PATHWAYS
1. SARS-CoV-2 genome sequencing and promising druggable targets
2. Signaling pathways implicated in SARS-CoV2 infection
3. Roles of membrane lipids and lipid synthesis inhibitors in the propagation of coronavirus disease
4. Potential Drugs in SARS-CoV-2 Treatment: Key Features and Mechanisms of Actions
PART 2: COMPUTATIONAL APPROACHES
5. Application of computational tools for coronavirus drug discovery
6. In silico Approaches in Drug Discovery for SARS-CoV-2
7. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies
8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19
9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2
10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins
11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals
12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry
- Edition: 1
- Latest edition
- Published: July 12, 2022
- Language: English
CE
Chukwuebuka Egbuna
Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.
Affiliations and expertise
Africa Centre of Excellence in Public Health and Toxicological Research, University of Port Harcourt, NigeriaRead Coronavirus Drug Discovery on ScienceDirect